Raajit K. Rampal

11.0k total citations
178 papers, 3.3k citations indexed

About

Raajit K. Rampal is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Raajit K. Rampal has authored 178 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Genetics, 120 papers in Hematology and 51 papers in Molecular Biology. Recurrent topics in Raajit K. Rampal's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (127 papers), Acute Myeloid Leukemia Research (74 papers) and Chronic Myeloid Leukemia Treatments (70 papers). Raajit K. Rampal is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (127 papers), Acute Myeloid Leukemia Research (74 papers) and Chronic Myeloid Leukemia Treatments (70 papers). Raajit K. Rampal collaborates with scholars based in United States, United Kingdom and Italy. Raajit K. Rampal's co-authors include Ross L. Levine, Omar Abdel‐Wahab, Robert S. Haltiwanger, John Mascarenhas, María E. Figueroa, Srđan Verstovšek, Kelvin B. Luther, Neal Rosen, Ronald Hoffman and Andrew Dunbar and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Biological Chemistry.

In The Last Decade

Raajit K. Rampal

160 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raajit K. Rampal United States 30 1.7k 1.6k 1.6k 632 495 178 3.3k
Henrik Hjorth‐Hansen Norway 27 774 0.4× 937 0.6× 1.9k 1.2× 469 0.7× 859 1.7× 74 2.8k
Philip Beer United Kingdom 32 2.4k 1.4× 2.7k 1.7× 2.3k 1.5× 955 1.5× 722 1.5× 87 4.6k
Hana Raslová France 29 2.4k 1.4× 3.2k 1.9× 3.1k 2.0× 1.1k 1.7× 785 1.6× 75 5.2k
Thomas Mercher France 27 2.4k 1.4× 1.9k 1.2× 2.0k 1.3× 683 1.1× 469 0.9× 53 4.0k
Catherine Lacout France 22 2.2k 1.3× 3.3k 2.0× 2.6k 1.7× 1.3k 2.0× 740 1.5× 47 4.3k
Valeria Visconte United States 29 1.4k 0.8× 860 0.5× 1.8k 1.2× 240 0.4× 406 0.8× 181 3.2k
Yaping Shou United States 25 1.1k 0.6× 1.5k 0.9× 1.8k 1.2× 826 1.3× 686 1.4× 68 3.1k
Philipp Erben Germany 32 830 0.5× 1.8k 1.1× 2.0k 1.3× 1.5k 2.4× 640 1.3× 161 3.8k
Sabine Cerny‐Reiterer Austria 29 808 0.5× 576 0.4× 849 0.5× 471 0.7× 453 0.9× 65 2.2k
Christoph Walz Germany 25 650 0.4× 679 0.4× 792 0.5× 694 1.1× 375 0.8× 70 2.1k

Countries citing papers authored by Raajit K. Rampal

Since Specialization
Citations

This map shows the geographic impact of Raajit K. Rampal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raajit K. Rampal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raajit K. Rampal more than expected).

Fields of papers citing papers by Raajit K. Rampal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raajit K. Rampal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raajit K. Rampal. The network helps show where Raajit K. Rampal may publish in the future.

Co-authorship network of co-authors of Raajit K. Rampal

This figure shows the co-authorship network connecting the top 25 collaborators of Raajit K. Rampal. A scholar is included among the top collaborators of Raajit K. Rampal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raajit K. Rampal. Raajit K. Rampal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jinqin, Sophia Zhao, Tiejun Qin, et al.. (2025). The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms. Blood. 147(9). 946–959.
2.
Mascarenhas, John, Raajit K. Rampal, Prithviraj Bose, et al.. (2024). Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.. Journal of Clinical Oncology. 42(16_suppl). TPS6594–TPS6594. 1 indexed citations
3.
4.
Masárová, Lucia, John Mascarenhas, Raajit K. Rampal, et al.. (2024). Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer. 131(1). e35661–e35661. 4 indexed citations
5.
6.
Pemmaraju, Naveen, et al.. (2023). Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leukemia & lymphoma. 64(6). 1063–1081. 22 indexed citations
7.
Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2023). Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.. Journal of Clinical Oncology. 41(16_suppl). 7018–7018. 1 indexed citations
8.
Gupta, Vikas, John Mascarenhas, Marina Kremyanskaya, et al.. (2023). Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Advances. 7(18). 5421–5432. 4 indexed citations
9.
Mascarenhas, John, Hélène F.E. Gleitz, Helen T. Chifotides, et al.. (2022). Biological drivers of clinical phenotype in myelofibrosis. Leukemia. 37(2). 255–264. 28 indexed citations
10.
Rampal, Raajit K., Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, et al.. (2021). Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clinical Cancer Research. 27(12). 3456–3468. 14 indexed citations
11.
Bewersdorf, Jan Philipp, Smith Giri, Rong Wang, et al.. (2020). Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia. 20(10). e712–e723. 11 indexed citations
12.
Bewersdorf, Jan Philipp, Smith Giri, Rong Wang, et al.. (2020). Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia. 35(6). 1643–1660. 39 indexed citations
13.
Mughal, Tariq I., Naveen Pemmaraju, Bethan Psaila, et al.. (2020). Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematological Oncology. 38(5). 654–664. 1 indexed citations
14.
King, Amber C., et al.. (2019). Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient. SHILAP Revista de lepidopterología. 7(10). 1989–1993. 7 indexed citations
15.
Rampal, Raajit K., Srđan Verstovšek, Sean M. Devlin, et al.. (2019). Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood. 134(Supplement_1). 4163–4163. 26 indexed citations
16.
Marcellino, Bridget K., Ronald Hoffman, Joseph Tripodi, et al.. (2018). Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Advances. 2(24). 3581–3589. 46 indexed citations
17.
Diamond, Eli L., Benjamin H. Durham, Ahmet Doǧan, et al.. (2017). Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders. Blood. 130. 257–257. 3 indexed citations
18.
Menghrajani, Kamal, Franck Rapaport, Caroline McNamara, et al.. (2017). SETBP1 and NRAS Mutations Are Frequent Events in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML) Lacking JAK-STAT Activating Mutations. Blood. 130. 203–203. 1 indexed citations
19.
Hyman, David M., Eli L. Diamond, Cecile Rose T. Vibat, et al.. (2014). Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery. 5(1). 64–71. 84 indexed citations
20.
Abdel‐Wahab, Omar, Virginia M. Klimek, Agnès Viale, et al.. (2014). Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery. 4(5). 538–545. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henrik Hjorth‐Hansen Breakdown of academic impact, for papers by Philip Beer Breakdown of academic impact, for papers by Hana Raslová Breakdown of academic impact, for papers by Thomas Mercher Breakdown of academic impact, for papers by Catherine Lacout Breakdown of academic impact, for papers by Valeria Visconte Breakdown of academic impact, for papers by Yaping Shou Breakdown of academic impact, for papers by Philipp Erben Breakdown of academic impact, for papers by Sabine Cerny‐Reiterer Breakdown of academic impact, for papers by Christoph Walz
Rankless by CCL
2026